US 12,102,639 B2
Imipridones for gliomas
Joshua E. Allen, New Haven, CT (US); Martin Stogniew, Lakewood Ranch, FL (US); and Varun Vijay Prabhu, Philadelphia, PA (US)
Assigned to Oncoceutics, Inc., Philadelphia, PA (US)
Filed by Oncoceutics, Inc., Philadelphia, PA (US)
Filed on Feb. 9, 2021, as Appl. No. 17/171,532.
Application 17/171,532 is a division of application No. 16/526,444, filed on Jul. 30, 2019, granted, now 10,946,022.
Application 16/526,444 is a division of application No. 16/204,964, filed on Nov. 29, 2018, granted, now 10,369,154, issued on Aug. 6, 2019.
Application 16/204,964 is a division of application No. 15/947,840, filed on Apr. 8, 2018, granted, now 10,172,862, issued on Jan. 8, 2019.
Application 15/947,840 is a continuation in part of application No. PCT/US2017/015608, filed on Jan. 30, 2017.
Claims priority of provisional application 62/581,478, filed on Nov. 3, 2017.
Prior Publication US 2021/0236499 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/00 (2018.01)] 19 Claims
 
1. A method of treating a brain cancer in a patient in need thereof, the method comprising:
administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of compound (1)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, at a predetermined dose with a frequency selected from one or more of:
a) once daily;
b) according to an infrequent dosing regimen;
c) according to a frequent dosing regimen;
d) once weekly;
e) once every four weeks;
f) twice a week;
g) once every two weeks;
h) once every three weeks; and
i) in a repeated cycle of once weekly, once every two weeks, once every three weeks, once every four weeks,
wherein the cancer has a histone H3 K27M mutation.